Drugs − Real World Outcomes
Brivaracetam Retention Rate and Seizure Outcomes in Patients with Drug-resistant Focal Epilepsy Included in the Medical Need Program in Belgium: A Real-World, Multicenter, Chart Review
Chantal Depondt
1∙ Wim Van Paesschen
2∙ Kenou van Rijckevorsel
3∙ Iryna Leunikava
4∙ France Ferrière
51
Reference Center for the Treatment of Refractory Epilepsy, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium
2
Refractory Epilepsy Center, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
3
Centre Hospitalier Neurologique William Lennox, Allée de Clerlande 6, 1340 Ottignies, Belgium
4
UCB Pharma, Alfred-Nobel-Straße 10, 40789 Monheim am Rhein, Germany
5
UCB Pharma, Allée de la Recherche 60, 1070 Brussels, Belgium
Corresponding author: email: france.ferriere@ucb.com
Online Resource 1 Concomitant AEDs at brivaracetam treatment start and at last follow- up in the patients included in the main analyses
Concomitant AED N = 175 N = 166
At treatment start At last follow-up
n % n %
Lacosamide 67 38.3 58 34.9
Levetiracetam 59 33.7 24 14.5
Lamotrigine 57 32.6 49 29.5
Carbamazepine 47 26.9 43 25.9
Valproic acid 43 24.6 40 24.1
Topiramate 43 24.6 36 21.7
Oxcarbazepine 21 12.0 20 12.0
Perampanel 20 11.4 12 7.2
Phenytoin 16 9.1 16 9.6
Pregabalin 14 8.0 14 8.4
Phenobarbital 13 7.4 14 8.4
Retigabine 10 5.7 6 3.6
Vigabatrin 5 2.9 4 2.4
Ethosuximide 2 1.1 1 0.6
Rufinamide 1 0.6 2 1.2
Clobazam 30 17.1 27 16.3
Clonazepam 19 10.9 19 11.4
Lorazepam 9 5.1 6 3.6
Diazepam 3 1.7 2 1.2
Midazolam 0 0.0 1 0.6
Othera 8 4.6 9 5.4
Main combinations
Lamotrigine, lacosamide 5 2.9 4 2.4
Lamotrigine, topiramate 4 2.3 2 1.2
Levetiracetam, lacosamide 4 2.3 3 1.8
Lacosamide, valproic acid 1 0.6 5 3.0
Carbamazepine, lacosamide 4 2.3 4 2.4
Clobazam, lamotrigine 1 0.6 5 3.0
AED antiepileptic drug, N total number of patients, n/% number/percentage of patients within each category. aOther at treatment start (number of participants) = padsevonil (n = 1); tiagabine (n = 2), primidone (n = 1), gabapentin (n = 1), acetazolamide (n = 2), ethyl loflazepate (n = 2), sulthiame (n = 1). Other at last follow-up = tiagabine (n = 2), padsevonil (n = 1), gabapentin (n = 1), sulthiame (n = 1). Note: patients could be on multiple ‘Other’ AEDs
Online Resource 2 Treatment emergent safety events spontaneously reported by the physicians
Safety event Number of events reported
Psychiatric
Aggression 15
Mood change (depression) 5
Nervousness 3
Suicidal ideation 3
Irritability 2
Anxiety 2
Concentration difficulties 1
Delirium 1
Memory impairment 1
CNS-related
Dizziness 5
Headache 5
Fatigue 2
Drowsiness 2
Insomnia 2
Other
Thrombocytopenia 6
Loss of appetite 3
Nausea 3
Stable or slight gamma-GT elevation 2
Rash 2
Alopecia 2
Muscular tension 1
Abdominal pain 1
Digestive problems (constipation) 1
Anorexia 1
Increased appetite 1
Weight gain 1
Erectile dysfunction 1
CNS central nervous system, gamma-GT gamma-glutamyl transferase
